Lee Ha Youn, Kang Hye-Rin, Lee Jung-Kyu, Heo Eun Young, Choi Seung Ho, Kim Deog Kyeom
Division of Pulmonary, Department of Internal Medicine, Serim General Hospital, Incheon, Korea.
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Veterans Health Service Medical Center, Seoul, Korea.
Ann Palliat Med. 2020 Sep;9(5):3115-3122. doi: 10.21037/apm-20-850. Epub 2020 Jul 20.
Although Helicobacter pylori (H. pylori) infection has long been associated with many extragastric diseases, its long-term effects on declining lung function and the development of chronic obstructive pulmonary disease (COPD) remains controversial.
We conducted a retrospective study in a health screening population (Gene-Environment of Interaction and Phenotype Cohort at Seoul National University Gangnam Health Center in Korea) recruited from 2004 to 2015. The annual decline rates of lung function and the risk for COPD were compared to the seropositivity for H. pylori. We also assessed the impact of the H. pylori eradication treatment on lung function.
Among 3,619 subjects, 1,849 subjects (51.1%) tested positive for H. pylori-specific IgG. In the first year, 95 (2.6%) patients were diagnosed with COPD. however, there was no difference in seropositivity for H. pylori in patients with COPD compared to non-COPD subjects (P=0.756). There was no significant difference in the incidence of COPD between the seronegative (2.2%) and the seropositive group (2.0%; P=0.728) even during the follow-up period. The decline rates of the mean FVC and FEV1 were not different between the seronegative and seropositive group (35.38 vs. 34.34 mL/year for FVC, P=0.389; 39.23 vs. 37.49 mL/year for FEV1, P=0.086). The eradication treatment for H. pylori did not affect the decline rates of mean FVC and FEV1.
Infection or eradication treatment of H. pylori was not associated with the decline of lung function or COPD progression in this general population health screening. As a result, H. pylori may not be a significant contributor to deteriorating lung function.
尽管幽门螺杆菌(H. pylori)感染长期以来一直与许多胃外疾病相关,但其对肺功能下降和慢性阻塞性肺疾病(COPD)发展的长期影响仍存在争议。
我们对2004年至2015年招募的健康筛查人群(韩国首尔国立大学江南健康中心的基因 - 环境相互作用与表型队列)进行了一项回顾性研究。将肺功能的年下降率和COPD风险与幽门螺杆菌血清阳性情况进行比较。我们还评估了幽门螺杆菌根除治疗对肺功能的影响。
在3619名受试者中,1849名受试者(51.1%)幽门螺杆菌特异性IgG检测呈阳性。第一年,95名(2.6%)患者被诊断为COPD。然而,与非COPD受试者相比,COPD患者的幽门螺杆菌血清阳性率没有差异(P = 0.756)。即使在随访期间,血清阴性组(2.2%)和血清阳性组(2.0%;P = 0.728)的COPD发病率也没有显著差异。血清阴性组和血清阳性组的平均用力肺活量(FVC)和第一秒用力呼气容积(FEV1)下降率没有差异(FVC分别为35.38 vs. 34.34 mL/年,P = 0.389;FEV1分别为39.23 vs. 37.49 mL/年,P = 0.086)。幽门螺杆菌根除治疗并未影响平均FVC和FEV1的下降率。
在该普通人群健康筛查中,幽门螺杆菌感染或根除治疗与肺功能下降或COPD进展无关。因此,幽门螺杆菌可能不是肺功能恶化的重要因素。